Idarubicin Hydrochloride

Spezifikationen

57852-57-0CAS-Nummer

260-990-7EG-Nummer

(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochlorideIUPAC-Name

C26H28ClNO9Chemische Formel

534 g/molMolekulargewicht

idarubicin hydrochloride; 57852-57-0; Idarubicin Hcl; Idamycin; Idamycin PFS; IMI 30; DTXSID0047797; 5VV3MDU5IE; Idarubicin hydrochloride PFS; IMI-30; NSC-256439; DTXCID0027775; NSC256439; RefChem:56927; Hydrochloride, Idarubicin; IMI30; (2S,4S)-2-Acetyl-4-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-2,5,12-trihydroxy-1,2,3,4-tetrahydrotetracene-6,11-dione monohydrochloride; Idarubicin (hydrochloride); MFCD00897212; 4-Demethoxydaunorubicin hydrochloride; CPD000466355; MLS001401448; (7S,9S)-9-acetyl-7-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride; SMR000466355; CAS-57852-57-0; NCGC00093976-03; UNII-5VV3MDU5IE; SR-01000075934; Idamycin (TN); EINECS 260-990-7; Idarubicin hydrochloride [USAN:USP:INN]; Idarubicin hydrochloride?; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; SCHEMBL4838; C26H28ClNO9; MLS000759470; orb1224603; orb1301162; CHEMBL1200976; SCHEMBL29367370; CHEBI:31686; JVHPTYWUBOQMBP-RVFAQHLVSA-N; GLXC-07976; KUC110342C; EX-A1148; Tox21_111236; HY-17381R; IDARUBICIN HYDROCHLORIDE [MI]; s1228; Idarubicin hydrochloride (JP18/USP); IDARUBICIN HYDROCHLORIDE [JAN]; AKOS025402118; Idarubicin (hydrochloride) (Standard); Tox21_111236_1; AC-5255; CCG-100886; EBC-101076; FI24535; IDARUBICIN HYDROCHLORIDE [USAN]; NC00136; Daunomycin, 4-demethoxy-, hydrochloride; IDARUBICIN HYDROCHLORIDE [MART.]; IDARUBICIN HYDROCHLORIDE [VANDF]; IDARUBICIN HYDROCHLORIDE [USP-RS]; IDARUBICIN HYDROCHLORIDE [WHO-DD]; NCGC00093976-08; (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside, hydrochloride; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride; AS-75944; HY-17381; KSC-230-185-1; Idarubicin Hydrochloride (1mg/mL in DMSO); I1400; Idarubicin Hydrochloride (1 mg/mL in DMSO); NS00087283; T6010; Idarubicin Hydrochloride (10 mg/mL in DMSO); IDARUBICIN HYDROCHLORIDE [ORANGE BOOK]; D01747; IDARUBICIN HYDROCHLORIDE [USP MONOGRAPH]; F864036; SR-01000075934-5; Q27262943; (1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside--hydrogen chloride (1/1); (7S,9S)-9-acetyl-7-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dionehydrochloride; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S-cis)-9-Acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione hydrochloride; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-?-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione hydrochloride; 1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE, HYDROCHLORIDE; 5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXYHYDROCHLORIDE, (7S-CIS)-; 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-cis)-; 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, hydrochloride (1:1), (7S,9S)-Synonyme